0.6506
price down icon11.74%   -0.0865
after-market Dopo l'orario di chiusura: .65 -0.0006 -0.09%
loading
Precedente Chiudi:
$0.7371
Aprire:
$0.7161
Volume 24 ore:
1.46M
Relative Volume:
1.15
Capitalizzazione di mercato:
$64.53M
Reddito:
$153.73M
Utile/perdita netta:
$-106.79M
Rapporto P/E:
-0.3655
EPS:
-1.78
Flusso di cassa netto:
$-115.93M
1 W Prestazione:
-15.54%
1M Prestazione:
-59.08%
6M Prestazione:
-81.20%
1 anno Prestazione:
-88.48%
Intervallo 1D:
Value
$0.6302
$0.728
Intervallo di 1 settimana:
Value
$0.6302
$0.798
Portata 52W:
Value
$0.6302
$5.88

Sutro Biopharma Inc Stock (STRO) Company Profile

Name
Nome
Sutro Biopharma Inc
Name
Telefono
650-392-8412
Name
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Dipendente
0
Name
Cinguettio
@SutroBio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
STRO's Discussions on Twitter

Confronta STRO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
STRO
Sutro Biopharma Inc
0.6506 64.53M 153.73M -106.79M -115.93M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-17 Downgrade H.C. Wainwright Buy → Neutral
2025-03-14 Downgrade BofA Securities Buy → Underperform
2025-03-14 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 Downgrade Wedbush Outperform → Neutral
2024-05-08 Iniziato BofA Securities Buy
2023-11-09 Iniziato Deutsche Bank Buy
2023-10-06 Iniziato Oppenheimer Outperform
2023-03-21 Downgrade Wells Fargo Overweight → Equal Weight
2022-08-18 Ripresa Wells Fargo Overweight
2021-06-18 Iniziato H.C. Wainwright Buy
2020-12-03 Iniziato Stifel Buy
2020-09-02 Iniziato Jefferies Buy
2020-07-16 Iniziato Wells Fargo Overweight
2020-01-13 Iniziato SunTrust Buy
2019-10-07 Iniziato BTIG Research Buy
2019-07-18 Iniziato Deutsche Bank Buy
2019-04-29 Iniziato H.C. Wainwright Buy
2018-10-22 Iniziato JMP Securities Mkt Outperform
2018-10-22 Iniziato Piper Jaffray Overweight
2018-10-22 Iniziato Wedbush Outperform
Mostra tutto

Sutro Biopharma Inc Borsa (STRO) Ultime notizie

pulisher
02:20 AM

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

02:20 AM
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World

Mar 23, 2025
pulisher
Mar 20, 2025

Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle

Mar 19, 2025
pulisher
Mar 19, 2025

The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online

Mar 19, 2025
pulisher
Mar 18, 2025

Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Array Technologies, Nextracker, Sutro Biopharma - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal

Mar 16, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro prioritizes preclinical ADC programs - BioWorld Online

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter

Mar 14, 2025
pulisher
Mar 14, 2025

This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum

Mar 14, 2025
pulisher
Mar 14, 2025

Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8 - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating -March 14, 2025 at 06:39 am EDT - Marketscreener.com

Mar 14, 2025

Sutro Biopharma Inc Azioni (STRO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):